Skip to main content
. 2020 Jul 17;83(10):923–930. doi: 10.1097/JCMA.0000000000000389

Fig. 6.

Fig. 6.

Effects of rosiglitazone alone or combined with bexarotene on the protein expression of sodium/iodide symporter (NIS) and thyroglobulin in BCPAP and follicular thyroid cancer (FTC)-133 cells. A, Thyroid cancer BCPAP cells were treated with 10 μM rosiglitazone (R) alone or in combination with different concentrations of bexarotene (B) under normoxic or hypoxic conditions for 24 h. The protein levels were detected by Western blot analysis. B, Thyroid cancer FTC-133 cells were treated with 10 μM R alone or in combination with different concentrations of bexarotene (B) under normoxic or hypoxic conditions for 24 h. The protein levels were detected by Western blot analysis. CTL, control; HIF, hypoxia-inducible factors.